KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Research & Development: 2011-2025

Historic Research & Development for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Sep 2025 value amounting to $29.4 million.

  • Supernus Pharmaceuticals' Research & Development rose 1.14% to $29.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $107.1 million, marking a year-over-year increase of 3.44%. This contributed to the annual value of $108.8 million for FY2024, which is 18.78% up from last year.
  • Supernus Pharmaceuticals' Research & Development amounted to $29.4 million in Q3 2025, which was up 32.79% from $22.1 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' Research & Development's 5-year high stood at $34.3 million during Q1 2021, with a 5-year trough of $15.5 million in Q2 2021.
  • For the 3-year period, Supernus Pharmaceuticals' Research & Development averaged around $25.3 million, with its median value being $24.9 million (2024).
  • Per our database at Business Quant, Supernus Pharmaceuticals' Research & Development surged by 81.02% in 2021 and then slumped by 39.21% in 2022.
  • Quarterly analysis of 5 years shows Supernus Pharmaceuticals' Research & Development stood at $21.1 million in 2021, then dropped by 15.68% to $17.8 million in 2022, then skyrocketed by 31.35% to $23.3 million in 2023, then climbed by 22.70% to $28.6 million in 2024, then rose by 1.14% to $29.4 million in 2025.
  • Its Research & Development was $29.4 million in Q3 2025, compared to $22.1 million in Q2 2025 and $26.9 million in Q1 2025.